Rights issue in Camurus AB (SE) — SEK 400 million

Carnegie acted as joint global co-ordinator in the SEK 400 million rights issue in Camurus. Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. March 2019.